Comparison between Radioembolization and Transarterial chemoembolization in liver cancer treatment
Not Applicable
Recruiting
- Conditions
- hepatocellular carcinomaC22.0
- Registration Number
- RBR-8w9rzy
- Lead Sponsor
- Faculdade de Medicina de Botucatu/ Universidade Estadual Paulista
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- Not specified
Inclusion Criteria
Age of 18 years-old or older; hepatocellular carcinoma graded as intermediate or advanced; liver cirrhosis; performance status of 0 or 1 at the time of the treatment; with contrast-administrated imaging exams before the treatment to assess the treatment response.
Exclusion Criteria
Another neoplastic disease; incomplete study procedures; lack of imaging exams during the follow-up; other severe ilnesses in advanced stage that could be more harmful to the patient survival than the hepatocellular carcinoma and the liver cirrhosis, such as chronic obstructive pulmonar disease, cardiac insuficiency, immunosupression (caused by HIV infection or drug-induced) or dialytic kidney insuficiency; pregnant or lactating women.
Study & Design
- Study Type
- Intervention
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To assess the locoregional response according to the modified RECIST criteria, calculated by the measures of the tumor size in the arterial phase of the computadorized tomography performed before and after the procedures, in squared milimeters. ;To evaluate the changes of the tumor area in the arterial phase observed in the iodine-contrasted computed tomography, in squared milimeters.
- Secondary Outcome Measures
Name Time Method To assess the time to progression and the overall survival, measured in days.;To measure the time frame in which the patient lives without any signs of tumor progression and the time frame between the procedure and the patient death, measured in days.